BUSINESS

Japan Approves 1st Gene Panel Testing for IRD

June 6, 2023

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Sysmex said on June 5 that it has won Japanese regulatory approval for PrismGuide IRD Panel System, the first gene panel testing system for inherited retinal dystrophy (IRD) in the country. The clearance was granted on May 31. PrismGuide IRD,…

To read the full story

Novartis Rolls Out Luxturna in Japan, 2 Treatment Facilities Selected
August 31, 2023
Luxturna Priced at 49.6 Million Yen per Vial, Peak Sales Put at 500 Million Yen with 5 Patients
August 24, 2023
Drug Pricing Rules to Be Applied to Novartis’ Gene Therapy Luxturna
July 6, 2023
Japan Approves Novartis’ Gene Therapy Luxturna for Rare Eye Disease
June 27, 2023

BUSINESS

Half of Drug Makers Reluctantly Support G1 Rule Overhaul: Jiho Survey
March 12, 2026
FDA Resumes Review of Capricor/Nippon Shinyaku’s DMD Cell Therapy
March 12, 2026
Hisamitsu Starts Promotion of Yaz AGs under Bayer Alliance
March 11, 2026
Seagen ADC Patent Dispute Ends with Daiichi Sankyo Victory
March 11, 2026
Seikagaku Re-Files Herniated Disk Drug with US FDA
March 11, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Elevidys Opens New Era for DMD Treatments Targeting the Underlying Cause

By Shinya Sato

Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…